论文信息 - Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study - 字舞流文

Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study

To describe the efficacy and safety of biologics for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA).

S. Sartorelli | L. Dagna | A. Vaglio | V. Cottin | F. Maurier | C. Deligny | A. Aouba | G. Emmi | X. Puéchal | B. Godeau | M. Ruivard | L. Guillevin | B. Terrier | M. Jachiet | J. Kahn | M. Urban | C. de Moreuil | P. Bonniaud | N. Venhoff | J. Thiel | S. Faguer | G. Pugnet | M. Samson | P. Cathébras | F. Lifermann | H. Gil | M. Groh | C. Taillé | N. Girszyn | V. Rieu | A. Ruppert | A. Deroux | P. Smets | Laure Denis | Alice Canzian | C. Durel | V. Germain | S. Phin-Huynh | L. Denis | C. de Moreuil

[1] D. Jayne,et al. Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis , 2019, RMD Open.

[2] A. Vaglio,et al. Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis , 2017, Annals of the rheumatic diseases.

[3] S. Yancey,et al. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis , 2017, The New England journal of medicine.

[4] V. Cottin,et al. Anti‐IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg‐Strauss): Data on Seventeen Patients , 2016, Arthritis & rheumatology.

[5] P. Merkel,et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg–Strauss) , 2014, Annals of the rheumatic diseases.

[6] D A Bloch,et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). , 2010, Arthritis and rheumatism.

[7] David Steven Scott,et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3) , 2008, Annals of the rheumatic diseases.

[8] C. Ribi,et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. , 2008, Arthritis and rheumatism.

[9] L. Mouthon,et al. Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. , 2007, Arthritis and rheumatism.

[10] L. Mouthon,et al. Antineutrophil Cytoplasmic Antibodies and the ChurgStrauss Syndrome , 2005, Annals of Internal Medicine.

[11] Laura Pavone,et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. , 2005, Arthritis and rheumatism.

[12] C. Gordon,et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. , 1997, Arthritis and rheumatism.

[13] O. Lortholary,et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. , 1996, Medicine.